Molecular circuits of resolution in renal disease

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 1370-1385

  Börgeson, Emma ^a   Godson, Catherine ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Lipxoins; Protectins; Renal inflammation; Resolvins

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CD59 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; DOXORUBICIN; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXIN; LIPOXIN A; LIPOXIN B; NEUTRALIZING ANTIBODY; OMEGA 3 FATTY ACID; PROTECTIN D1; RESOLVIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTHMA; BIOSYNTHESIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COLITIS; COMPETITIVE INHIBITION; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETIC NEPHROPATHY; DRUG MEGADOSE; ENTERITIS; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; LOW DRUG DOSE; MACROPHAGE; MESANGIUM CELL; MOLECULAR DYNAMICS; NEPHRITIS; NONHUMAN; PATHOGENESIS; PERIODONTAL DISEASE; PERIODONTITIS; PERITONITIS; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; RENAL PROTECTION; REPERFUSION INJURY; RETINA NEOVASCULARIZATION; REVIEW; METABOLISM;

ANTIGENS, CD59; DOCOSAHEXAENOIC ACIDS; HUMANS; KIDNEY DISEASES; LIPOXINS;

EID: 77955888344     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.120     Document Type: Review

References (133)

1. Maderna, P. and Godson, C. (2009) Lipoxins: resolutionary road. Br. J. Pharmacol. 158, 947-959.
2. Serhan, C.N., Yacoubian, S., and Yang, R. (2008) Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3, 279-312.
3. Serhan, C.N. (2009) Systems approach to inflammation resolution: identification of novel anti-inflammatory and proresolving mediators. J. Thromb. Haemost. 7(Suppl 1), 44-48.
4. Serhan, C.N. and Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197.
5. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., and Serhan, C.N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619.
6. Ferenbach, D., Kluth, D.C., and Hughes, J. (2007) Inflammatory cells in renal injury and repair. Semin. Nephrol. 27, 250-259.
7. Wu, S.H., Liao, P.Y., Yin, P.L., Zhang, Y.M., and Dong, L. (2009) Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am. J. Pathol. 174, 115-122.
8. Rivero, A., Mora, C., Muros, M., Garcia, J., Herrera, H., and Navarro-Gonzalez, J.F. (2009) Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. (Lond.) 116, 479-492.
9. Serhan, C.N., Hamberg, M., and Samuelsson, B. (1984) Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 81, 5335-5339. (Pubitemid 14048742)
10. Serhan, C.N., Wong, P.Y., and Samuelsson, B. (1987) Nomenclature of lipoxins and related compounds derived from arachidonic acid and eicosapentaenoic acid. Prostaglandins 34, 201-204.
11. Serhan, C.N. (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids 73, 141-162.
12. Parkinson, J.F. (2006) Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm. Allergy Drug Targets 5, 91-106.
13. Serhan, C.N. (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137.
14. Lefer, A.M., Stahl, G.L., Lefer, D.J., Brezinski, M.E., Nicolaou, K.C., Veale, C.A., Abe, Y., and Smith, J.B. (1988) Lipoxins A4 and B4: comparison of icosanoids having bronchoconstrictor and vasodilator actions but lacking platelet aggregatory activity. Proc. Natl. Acad. Sci. U. S. A. 85, 8340-8344.
15. Brezinski, M.E. and Serhan, C.N. (1990) Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl. Acad. Sci. U. S. A. 87, 6248-6252.
16. Claria, J. and Serhan, C.N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U. S. A. 92, 9475-9479.
17. Morris, T., Stables, M., and Gilroy, D.W. (2006) New perspectives on aspirin and the endogenous control of acute inflammatory resolution. TheScientificWorldJOURNAL 6, 1048-1065.
18. Serhan, C.N. and Chiang, N. (2002) Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. TheScientificWorldJOURNAL 2, 169-204.
19. Chiang, N., Bermudez, E.A., Ridker, P.M., Hurwitz, S., and Serhan, C.N. (2004) Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 101, 15178-15183.
20. Birnbaum, Y., Ye, Y., Lin, Y., Freeberg, S.Y., Huang, M.H., Perez-Polo, J.R., and Uretsky, B.F. (2007) Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 83, 89-98.
21. Serhan, C.N., Maddox, J.F., Petasis, N.A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H.R., Colgan, S.P., and Madara, J.L. (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615.
22. Maddox, J.F., Hachicha, M., Takano, T., Petasis, N.A., Fokin, V.V., and Serhan, C.N. (1997) Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 272, 6972-6978.
23. Fiorucci, S., Wallace, J.L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Tseng, J.L., Suramanyam, B., Guilford, W.J., and Parkinson, J.F. (2004) A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. U. S. A. 101, 15736-15741.
24. Gewirtz, A.T., Collier-Hyams, L.S., Young, A.N., Kucharzik, T., Guilford, W.J., Parkinson, J.F., Williams, I.R., Neish, A.S., and Madara, J.L. (2002) Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168, 5260-5267.
25. Fiore, S., Ryeom, S.W., Weller, P.F., and Serhan, C.N. (1992) Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J. Biol. Chem. 267, 16168-16176.
26. Chiang, N., Serhan, C.N., Dahlen, S.E., Drazen, J.M., Hay, D.W., Rovati, G.E., Shimizu, T., Yokomizo, T., and Brink, C. (2006) The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487.
27. Fierro, I.M., Colgan, S.P., Bernasconi, G., Petasis, N.A., Clish, C.B., Arita, M., and Serhan, C.N. (2003) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 170, 2688-2694.
28. Leonard, M.O., Hannan, K., Burne, M.J., Lappin, D.W., Doran, P., Coleman, P., Stenson, C., Taylor, C.T., Daniels, F., Godson, C., Petasis, N.A., Rabb, H., and Brady, H.R. (2002) 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13, 1657-1662.
29. Levy, B.D., Kohli, P., Gotlinger, K., Haworth, O., Hong, S., Kazani, S., Israel, E., Haley, K.J., and Serhan, C.N. (2007) Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 178, 496-502.
30. O'Sullivan, T.P., Vallin, K.S., Shah, S.T., Fakhry, J., Maderna, P., Scannell, M., Sampaio, A.L., Perretti, M., Godson, C., and Guiry, P.J. (2007) Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem. 50, 5894-5902.
31. Petasis, N.A., Keledjian, R., Sun, Y.P., Nagulapalli, K.C., Tjonahen, E., Yang, R., and Serhan, C.N. (2008) Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg. Med. Chem. Lett. 18, 1382-1387.
32. Reville, K., Crean, J.K., Vivers, S., Dransfield, I., and Godson, C. (2006) Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J. Immunol. 176, 1878-1888.
33. Serhan, C.N. (2004) Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases? Expert Opin. Ther. Targets 8, 643-652.
34. Kantarci, A., Hasturk, H., and Van Dyke, T.E. (2006) Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 40, 144-163.
35. Kantarci, A. and Van Dyke, T.E. (2005) Lipoxin signaling in neutrophils and their role in periodontal disease. Prostaglandins Leukot. Essent. Fatty Acids 73, 289-299.
36. Lee, T.H., Horton, C.E., Kyan-Aung, U., Haskard, D., Crea, A.E., and Spur, B.W. (1989) Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-Lleucyl- L-phenylalanine. Clin. Sci. (Lond.) 77, 195-203.
37. Bandeira-Melo, C., Bozza, P.T., Diaz, B.L., Cordeiro, R.S., Jose, P.J., Martins, M.A., and Serhan, C.N. (2000) Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J. Immunol. 164, 2267-2271.
38. Qiu, F.H., Devchand, P.R., Wada, K., and Serhan, C.N. (2001) Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J. 15, 2736-2738.
39. Decker, Y., McBean, G., and Godson, C. (2009) Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am. J. Physiol. Cell Physiol. 296, C1420-1427.
40. Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N.A., Erwig, L., Rees, A.J., Savill, J., Brady, H.R., and Godson, C. (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497-2507.
41. Godson, C., Mitchell, S., Harvey, K., Petasis, N.A., Hogg, N., and Brady, H.R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667.
42. von der Weid, P.Y., Hollenberg, M.D., Fiorucci, S., and Wallace, J.L. (2004) Aspirin-triggered, cyclooxygenase-2- dependent lipoxin synthesis modulates vascular tone. Circulation 110, 1320-1325.
43. Fiore, S., Maddox, J.F., Perez, H.D., and Serhan, C.N. (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260.
44. Ye, R.D., Boulay, F., Wang, J.M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C.N., and Murphy, P.M. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119-161.
45. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.H., Yang, R., Petasis, N.A., and Serhan, C.N. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U. S. A. 107, 1660-1665.
46. McMahon, B., Stenson, C., McPhillips, F., Fanning, A., Brady, H.R., and Godson, C. (2000) Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J. Biol. Chem. 275, 27566-27575.
47. Wu, S.H., Wu, X.H., Lu, C., Dong, L., Zhou, G.P., and Chen, Z.Q. (2006) Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int. 69, 248-256.
48. Machado, F.S., Johndrow, J.E., Esper, L., Dias, A., Bafica, A., Serhan, C.N., and Aliberti, J. (2006) Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330-334.
49. Machado, F.S. and Aliberti, J. (2008) Role of lipoxin in the modulation of immune response during infection. Int. Immunopharmacol. 8, 1316-1319.
50. Tobin, D.M., Vary, J.C., Jr., Ray, J.P., Walsh, G.S., Dunstan, S.J., Bang, N.D., Hagge, D.A., Khadge, S., King, M.C., Hawn, T.R., Moens, C.B., and Ramakrishnan, L. (2010) The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717-730.
51. Herb, F., Thye, T., Niemann, S., Browne, E.N., Chinbuah, M.A., Gyapong, J., Osei, I., Owusu-Dabo, E., Werz, O., Rusch-Gerdes, S., Horstmann, R.D., and Meyer, C.G. (2008) ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum. Mol. Genet. 17, 1052-1060.
52. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., and Moussignac, R.L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
53. Schwab, J.M., Chiang, N., Arita, M., and Serhan, C.N. (2007) Resolvin E1 and protectin D1 activate inflammationresolution programmes. Nature 447, 869-874.
54. Hasturk, H., Kantarci, A., Ohira, T., Arita, M., Ebrahimi, N., Chiang, N., Petasis, N.A., Levy, B.D., Serhan, C.N., and Van Dyke, T.E. (2006) RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 20, 401-403.
55. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N., Petasis, N.A., Blumberg, R.S., and Serhan, C.N. (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A. 102, 7671-7676.
56. Connor, K.M., SanGiovanni, J.P., Lofqvist, C., Aderman, C.M., Chen, J., Higuchi, A., Hong, S., Pravda, E.A., Majchrzak, S., Carper, D., Hellstrom, A., Kang, J.X., Chew, E.Y., Salem, N., Jr., Serhan, C.N., and Smith, L.E. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873.
57. Duffield, J.S., Hong, S., Vaidya, V.S., Lu, Y., Fredman, G., Serhan, C.N., and Bonventre, J.V. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911.
58. Marcheselli, V.L., Hong, S., Lukiw, W.J., Tian, X.H., Gronert, K., Musto, A., Hardy, M., Gimenez, J.M., Chiang, N., Serhan, C.N., and Bazan, N.G. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807-43817.
59. Lukiw, W.J., Cui, J.G., Marcheselli, V.L., Bodker, M., Botkjaer, A., Gotlinger, K., Serhan, C.N., and Bazan, N.G. (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115, 2774-2783.
60. Kohli, P. and Levy, B.D. (2009) Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 158, 960-971.
61. Schieppati, A. and Remuzzi, G. (2005) Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. Suppl. S7-S10.
62. Ritz, E., Rychlik, I., Locatelli, F., and Halimi, S. (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 34, 795-808.
63. Liu, Y. (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1-12.
64. Kieran, N.E., Maderna, P., and Godson, C. (2004) Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65, 1145-1154.
65. Wu, S.H., Liao, P.Y., Dong, L., and Jiang, X.Y. (2006) [Protective effects of 15-methyl-lipoxin A4 on mesangioproliferative nephritis in rats]. Zhongguo Dang Dai Er Ke Za Zhi 8, 225-230.
66. Hassan, I.R. and Gronert, K. (2009) Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J. Immunol. 182, 3223-3232.
67. Neumayer, H.H., Heinrich, M., Schmissas, M., Haller, H., Wagner, K., and Luft, F.C. (1992) Amelioration of ischemic acute renal failure by dietary fish oil administration in conscious dogs. J. Am. Soc. Nephrol. 3, 1312-1320.
68. Dillon, J.J. (1997) Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J. Am. Soc. Nephrol. 8, 1739-1744.
69. Donadio, J.V. and Grande, J.P. (2002) IgA nephropathy. N. Engl. J. Med. 347, 738-748.
70. Kielar, M.L., Jeyarajah, D.R., Zhou, X.J., and Lu, C.Y. (2003) Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. J. Am. Soc. Nephrol. 14, 389-396.
71. Jia, Q., Shi, Y., Bennink, M.B., and Pestka, J.J. (2004) Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice. J. Nutr. 134, 1353-1361.
72. An, W.S., Kim, H.J., Cho, K.H., and Vaziri, N.D. (2009) Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am. J. Physiol. 297, F895-903.
73. McMahon, B., Mitchell, S., Brady, H.R., and Godson, C. (2001) Lipoxins: revelations on resolution. Trends Pharmacol. Sci. 22, 391-395.
74. Mayadas, T.N., Mendrick, D.L., Brady, H.R., Tang, T., Papayianni, A., Assmann, K.J., Wagner, D.D., Hynes, R.O., and Cotran, R.S. (1996) Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 49, 1342-1349.
75. Papayianni, A., Serhan, C.N., Phillips, M.L., Rennke, H.G., and Brady, H.R. (1995) Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47, 1295-1302.
76. Munger, K.A., Montero, A., Fukunaga, M., Uda, S., Yura, T., Imai, E., Kaneda, Y., Valdivielso, J.M., and Badr, K.F. (1999) Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. U. S. A. 96, 13375-13380.
77. Ricardo, S.D., van Goor, H., and Eddy, A.A. (2008) Macrophage diversity in renal injury and repair. J. Clin. Invest. 118, 3522-3530.
78. Martinez, F.O., Sica, A., Mantovani, A., and Locati, M. (2008) Macrophage activation and polarization. Front. Biosci. 13, 453-461.
79. Mosser, D.M. and Edwards, J.P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. 8, 958-969.
80. Duffield, J.S. (2003) The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci. (Lond.) 104, 27-38.
81. Wang, Y., Wang, Y.P., Zheng, G., Lee, V.W., Ouyang, L., Chang, D.H., Mahajan, D., Coombs, J., Wang, Y.M., Alexander, S.I., and Harris, D.C. (2007) Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 72, 290-299.
82. Maderna, P., Cottell, D.C., Berlasconi, G., Petasis, N.A., Brady, H.R., and Godson, C. (2002) Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am. J. Pathol. 160, 2275-2283.
83. Mitchell, D.A., Taylor, P.R., Cook, H.T., Moss, J., Bygrave, A.E., Walport, M.J., and Botto, M. (1999) Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J. Immunol. 162, 5676-5679.
84. Dong, X., Swaminathan, S., Bachman, L.A., Croatt, A.J., Nath, K.A., and Griffin, M.D. (2007) Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 71, 619-628.
85. Macconi, D., Chiabrando, C., Schiarea, S., Aiello, S., Cassis, L., Gagliardini, E., Noris, M., Buelli, S., Zoja, C., Corna, D., Mele, C., Fanelli, R., Remuzzi, G., and Benigni, A. (2009) Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J. Am. Soc. Nephrol. 20, 123-130.
86. Yang, D., Chen, Q., Le, Y., Wang, J.M., and Oppenheim, J.J. (2001) Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J. Immunol. 166, 4092-4098.
87. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., and Serhan, C.N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722.
88. Zhang, L., Wu, P., Jin, S.W., Yuan, P., Wan, J.Y., Zhou, X.Y., Xiong, W., Fang, F., and Ye, D.Y. (2007) Lipoxin A4 negatively regulates lipopolysaccharide-induced differentiation of RAW264.7 murine macrophages into dendritic-like cells. Chin. Med. J. 120, 981-987.
89. Anders, H.J., Vielhauer, V., and Schlondorff, D. (2003) Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 63, 401-415.
90. Furuichi, K., Kaneko, S., and Wada, T. (2009) Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin. Exp. Nephrol. 13, 9-14.
91. Kieran, N.E., Doran, P.P., Connolly, S.B., Greenan, M.C., Higgins, D.F., Leonard, M., Godson, C., Taylor, C.T., Henger, A., Kretzler, M., Burne, M.J., Rabb, H., and Brady, H.R. (2003) Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int. 64, 480-492.
92. Wu, S.H., Lu, C., Dong, L., Zhou, G.P., He, Z.G., and Chen, Z.Q. (2005) Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int. 68, 35-46. (Pubitemid 43181362)
93. Hachicha, M., Pouliot, M., Petasis, N.A., and Serhan, C.N. (1999) Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189, 1923-1930.
94. Jozsef, L., Zouki, C., Petasis, N.A., Serhan, C.N., and Filep, J.G. (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 99, 13266-13271.
95. Beinke, S. and Ley, S.C. (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. J. 382, 393-409.
96. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., and Willoughby, D.A. (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7, 1291-1297.
97. Panzer, U., Steinmetz, O.M., Turner, J.E., Meyer-Schwesinger, C., von Ruffer, C., Meyer, T.N., Zahner, G., Gomez-Guerrero, C., Schmid, R.M., Helmchen, U., Moeckel, G.W., Wolf, G., Stahl, R.A., and Thaiss, F. (2009) Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases. Am. J. Physiol. 297, F429-439.
98. Cao, S., Zhang, X., Edwards, J.P., and Mosser, D.M. (2006) NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 281, 26041-26050.
99. Baer, M., Dillner, A., Schwartz, R.C., Sedon, C., Nedospasov, S., and Johnson, P.F. (1998) Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappaB p50. Mol. Cell. Biol. 18, 5678-5689.
100. Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., and Fiore, S. (2000) Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164, 2660-2666.
101. Sodin-Semrl, S., Spagnolo, A., Mikus, R., Barbaro, B., Varga, J., and Fiore, S. (2004) Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int. J. Immunopathol. Pharmacol. 17, 145-156.
102. Hudert, C.A., Weylandt, K.H., Lu, Y., Wang, J., Hong, S., Dignass, A., Serhan, C.N., and Kang, J.X. (2006) Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. U. S. A. 103, 11276-11281.
103. Mitchell, D., Rodgers, K., Hanly, J., McMahon, B., Brady, H.R., Martin, F., and Godson, C. (2004) Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am. J. Pathol. 164, 937-946.
104. Mitchell, D., O'Meara, S.J., Gaffney, A., Crean, J.K., Kinsella, B.T., and Godson, C. (2007) The lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J. Biol. Chem. 282, 15606-15618.
105. Badr, K.F., DeBoer, D.K., Schwartzberg, M., and Serhan, C.N. (1989) Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc. Natl. Acad. Sci. U. S. A. 86, 3438-3442.
106. Wu, S.H., Wu, X.H., Liao, P.Y., and Dong, L. (2007) Signal transduction involved in protective effects of 15(R/S)-methyl- lipoxin A(4) on mesangioproliferative nephritis in rats. Prostaglandins Leukot. Essent. Fatty Acids 76, 173-180.
107. Katoh, T., Takahashi, K., DeBoer, D.K., Serhan, C.N., and Badr, K.F. (1992) Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. Am. J. Physiol. 263, F436-442.
108. Jarmi, T. and Agarwal, A. (2009) Heme oxygenase and renal disease. Curr. Hypertens. Rep. 11, 56-62.
109. Nakao, A., Neto, J.S., Kanno, S., Stolz, D.B., Kimizuka, K., Liu, F., Bach, F.H., Billiar, T.R., Choi, A.M., Otterbein, L.E., and Murase, N. (2005) Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am. J. Transplant. 5, 282-291.
110. Pittock, S.T., Norby, S.M., Grande, J.P., Croatt, A.J., Bren, G.D., Badley, A.D., Caplice, N.M., Griffin, M.D., and Nath, K.A. (2005) MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: pathophysiologic correlates. Kidney Int. 68, 611-622.
111. Biteman, B., Hassan, I.R., Walker, E., Leedom, A.J., Dunn, M., Seta, F., Laniado-Schwartzman, M., and Gronert, K. (2007) Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J. 21, 2257-2266.
112. Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Villela, C.G., and Fierro, I.M. (2005) Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am. J. Physiol. Cell Physiol. 289, C557-563.
113. Liu, Y. (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213-217.
114. Hewitson, T.D. (2009) Renal tubulointerstitial fibrosis: common but never simple. Am. J. Physiol. 296, F1239-1244.
115. Ryan, A., Murphy, M., Borgeson, E., Baker, N., Docherty, N., Godson, C. (2008) Novel fibro-suppressant activities of lipoxin A4 in renal cells. J. Am. Soc. Nephrol. 19, Abstr. TH-PO422.
116. Ronco, P., Lelongt, B., Piedagnel, R., and Chatziantoniou, C. (2007) Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin. Nephrol. 27, 352-362.
117. Zhou, X.Y., Li, Y.S., Wu, P., Wang, H.M., Cai, Z.Y., Xu, F.Y., and Ye, D.Y. (2009) Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells. Hepatol. Res. 39, 921-930.
118. Cezar-de-Mello, P.F., Vieira, A.M., Nascimento-Silva, V., Villela, C.G., Barja-Fidalgo, C., and Fierro, I.M. (2008) ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br. J. Pharmacol. 153, 956-965.
119. Kalluri, R. and Weinberg, R.A. (2009) The basics of epithelial- mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
120. Cheng, S., Pollock, A.S., Mahimkar, R., Olson, J.L., and Lovett, D.H. (2006) Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 20, 1898-1900.
121. Potenta, S., Zeisberg, E., and Kalluri, R. (2008) The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 99, 1375-1379.
122. Rodgers, K., McMahon, B., Mitchell, D., Sadlier, D., and Godson, C. (2005) Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 167, 683-694.
123. Tai, H.H., Tong, M., and Ding, Y. (2007) 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat. 83, 203-208.
124. Bottinger, E.P. (2007) TGF-beta in renal injury and disease. Semin. Nephrol. 27, 309-320.
125. Phillips, A. (2007) The role of proximal tubular cells in interstitial fibrosis: understanding TGF-beta1. Chang Gung Med. J. 30, 2-6.
126. Schiffer, M., Bitzer, M., Roberts, I.S., Kopp, J.B., ten Dijke, P., Mundel, P., and Bottinger, E.P. (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest. 108, 807-816.
127. Isaka, Y., Fujiwara, Y., Ueda, N., Kaneda, Y., Kamada, T., and Imai, E. (1993) Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 92, 2597-2601.
128. Ziyadeh, F.N., Hoffman, B.B., Han, D.C., Iglesias-De La Cruz, M.C., Hong, S.W., Isono, M., Chen, S., McGowan, T.A., and Sharma, K. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 97, 8015-8020.
129. Ma, L.J., Jha, S., Ling, H., Pozzi, A., Ledbetter, S., and Fogo, A.B. (2004) Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int. 65, 106-115.
130. Schnoor, M., Cullen, P., Lorkowski, J., Stolle, K., Robenek, H., Troyer, D., Rauterberg, J., and Lorkowski, S. (2008) Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J. Immunol. 180, 5707-5719.
131. Ng, Y.Y., Hou, C.C., Wang, W., Huang, X.R., and Lan, H.Y. (2005) Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int. Suppl. S83-91.
132. Wang, W., Huang, X.R., Li, A.G., Liu, F., Li, J.H., Truong, L.D., Wang, X.J., and Lan, H.Y. (2005) Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J. Am. Soc. Nephrol. 16, 1371-1383.
133. Poussu, A. (2001) Cloning and Characterization of Vear, a Novel Golgi-Associated Protein Involved in Vesicle Trafficking [Dissertation]. Oulu University, Finland.